Morgan Stanley, CLSA cut Cipla ratings on earnings
MUMBAI (Reuters) - Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd (CIPL.NS) a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
(Reporting by Abhishek Vishnoi and Rafael Nam; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- Miss America defends student suspended for asking her to prom
- UPDATE 3-Soccer-English premier league results and standings
- Calls to U.S. poison centers involving e-cigarettes jump - CDC
- Abdullah widens lead in Afghan presidential vote - latest count
- India passes halfway mark in election with BJP gaining strength
Nitin Gadkari, former president of the Bharatiya Janata Party and a member of the BJP’s manifesto committee, speaks to Reuters. Here are the edited excerpts. Full Article